Staying true to our初心, we set sail toward a brighter future—Wanbangde Pharmaceutical Group Holds Grand Appreciation Gala and New Product Launch Event

On January 21, the Wanbande Pharmaceutical Group’s Annual Customer Appreciation Conference and New Product Launch Event was grandly held at the Yaoda International Hotel in Wenling City. The event featured a rich agenda that closely aligned with the latest trends in the pharmaceutical industry, focusing on innovative drug research driven by independent intellectual property rights. The gathering aimed to accelerate the commercialization of scientific breakthroughs and further propel innovation and development within China’s traditional Chinese medicine sector. Experts from organizations such as the China Association for Pharmaceutical Enterprise Management, the Shanghai Institute of Materia Medica under the Chinese Academy of Sciences, Zhejiang University, and Peking University Third Hospital, along with hundreds of industry professionals, partners, and loyal customers, came together to witness the exciting launch of Wanbande Pharmaceutical Group’s groundbreaking new products.

The meeting began with a welcoming speech delivered by Chairman Zhao Shouming. He provided a detailed overview of Wanbangde Pharmaceutical Group’s achievements in 2017, highlighting advancements in new product development, brand building, capital expansion, and the establishment of industry standards. He then outlined the Group’s ambitious vision for the future and expressed his sincere hope to collaborate closely with industry experts, scholars, and partners across the pharmaceutical value chain, working together to drive transformative growth in the healthcare sector and collectively embracing the vital mission of revitalizing China’s traditional Chinese medicine industry.

Yu Mingde, Honorary Chairman of the China Association for Pharmaceutical Enterprise Management, kicked off the conference by delivering a report titled "Analysis of the Pharmaceutical Industry Landscape and Key New Policies." He highlighted that over the past two decades, a series of groundbreaking policy initiatives—driven by widespread industry attention, advocacy from stakeholders, and consensus among experts—have significantly bolstered innovation, accelerated industrial transformation and upgrading, and injected sustained momentum into the sector, ultimately proving highly beneficial for its growth. Following his remarks, a distinguished panel of experts took the stage to delve into critical topics, including "Research Progress and Future Prospects of Huperzine A, an Alzheimer's Disease Treatment," "A Secondary Development Study Report on Ginkgo Biloba Dropping Pills," "Clinical Applications of Inhalation Ammonium Bromide Solution," "Introduction to the Clinical Use of Phloroglucinol Injection," "Clinical Application Insights into Huperzine A Injection," and "Clinical Positioning Analysis of Total Saponins from Gynostemma Pentaphyllum Granules." The discussions were met with enthusiastic engagement from the audience, creating a vibrant and dynamic atmosphere throughout the event.

At the conclusion of the meeting, the leadership team from Wanbangde Pharmaceutical Group held a product seminar with partners and distributors from across the country. Representatives from the partner and distributor network actively participated, sharing valuable insights and suggestions on topics such as academic support for products, strategies for market expansion, differentiated brand positioning among related product lines, and initiatives related to corporate social responsibility funds. Chairman Zhao Shouming attentively listened to the participants' remarks and emphasized that the company’s growth would not be possible without the unwavering support of its partners and distributors. Looking ahead, he stated that the company will further clarify its strategic positioning, refine its development roadmap, and dedicate full efforts to both promoting new products through robust academic outreach and advancing the development of key product lines. This, he added, will help elevate the company’s brand visibility and strengthen its competitive edge, ultimately driving higher market share nationwide. Additionally, he pledged to leverage the combined strengths of all stakeholders, fostering a collaborative partnership model that benefits both the company and its distributors.

Following the event, Wanbande Pharmaceutical Group hosted a thank-you dinner, bringing together over 300 attendees. The evening’s prize draw session took the atmosphere to its peak, with the company generously rewarding distributors with coveted prizes such as iPhone 10s, iPads, and smart wristbands. The meeting concluded successfully amid laughter and joyful celebrations.

Chairman Zhao Shouming delivers a welcome speech.

Chinese Academy of Engineering Academician Tang Xican poses for a commemorative photo with Chen An, Executive Deputy General Manager of Wanbangde Pharmaceutical.

Wanbangde Pharmaceutical Group Appreciation Annual Meeting & New Product Launch Event

New Product Discussion Session

Yu Mingde, Honorary Chairman of the China Association for Pharmaceutical Enterprise Management, delivers a report.

Researcher Haiyan Zhang from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, delivers a report.

Chairman Zhao Shouming and Vice Chairman Zhuang Hui presented awards to their partners.